RTP Pharma

RTP Pharma was a biopharmaceutical company specializing in the development of proprietary drug delivery technologies designed to improve the formulation of poorly water-soluble drugs. The company's core platform, the Insoluble Drug Delivery (IDD) technology, utilized microparticle and nanoparticle engineering to enhance the bioavailability and efficacy of various therapeutic agents. RTP Pharma was notably acquired by SkyePharma in 2001 to bolster its drug delivery portfolio, leading to the commercialization of products like Triglide for the treatment of hyperlipidemia. The company operated facilities in both Research Triangle Park, North Carolina, and Montreal, Canada. Its technology was instrumental in overcoming solubility challenges for a wide range of small molecule therapeutics. Following the acquisition, its operations were integrated into SkyePharma's injectable and oral delivery divisions.